Interviews


Archive Interviews before 2011

Archive Interviews before 2007

Issue 671: August 11, 2017

671Ryan Sysko, CEO and Founder, Amalgam Rx, Inc., on delivering better health outcomes with apps.

Issue 669: July 28, 2017

669Mark Swindells, Ph.D., Chief Operating Officer, Exscientia, Ltd., on automating drug design.

Issue 668: July 21, 2017

668a668bAmy Schulman, Co-Founder and Chief Executive Officer, and Jessica Ballinger, Vice President of Reimbursement and Strategic Alliances, Lyndra, Inc., on moving from daily dosing to weekly dosing and beyond.

Issue 667: July 14, 2017

667David Merryman, Ph.D., Associate Professor of Biomedical Engineering, Pharmacology, Medicine, and Pediatrics, and  Associate Chair of Biomedical Engineering, Vanderbilt University, on blocking cadherin-11 as a potential treatment for calcific aortic valve disease.

Issue 664: June 16, 2017

664Noah Craft, MD, PhD, DTMH, Co-Founder and CEO, Science 37, on bringing clinical trials to the homes of patients.

Issue 660: May 19, 2017

660Michael Levin, Ph.D., Professor, Vannevar Bush Chair, and Director, Allen Discovery Center at Tufts University, and Tufts Center for Regenerative and Developmental Biology, on treating atopic dermatitis through autografts of benign bacteria.

Issue 657: April 28, 2017

657a657bRobert McNeil, Ph.D., Chief Executive Officer, and Donald M. Black, M.D., Chief Medical Officer, DalCor Pharmaceuticals, on exploring the limits of brain plasticity.

Issue 656: April 21, 2017

656Teruaki Nakatsuji, Ph.D., Project Scientist, Department of Dermatology, UC San Diego School of Medicine, on treating atopic dermatitis through autografts of benign bacteria.

Issue 655: April 7, 2017

655Milton H. Werner, Ph.D., Founder, President, and CEO, Inhibikase Therapeutics, on developing a disease modifying treatment for Parkinson’s disease.

Issue 654: March 31, 2017

654Michael Snyder, Ph.D., Stanford W. Ascherman Professor and Chair, Department of Genetics, and Director, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, on bringing wearable devices into clinical use.

Issue 653: March 24, 2017

653Pierre Beauparlant, Ph.D., Chief Business Officer, Diazon Pharmaceuticals Inc., on developing a potent microtubule-targeting agent with less toxicity.

Issue 651: March 10, 2017

651Michael Hooven, President and CEO, Enable Injections, Inc., on improving the way biologics are delivered.

Issue 649: February 24, 2017

649Jay Yourist, Ph.D., President & Chief Executive Officer, Nuovo Biologics LLC, on developing treatments for animals, and possibly humans.

Issue 648: February 17, 2017

648Tim Errington, Ph.D., Metascience Manager, Center for Open Science, on the difficulties of reproducing research results.

Issue 646: February 3, 2017

646Stanley Kim, Co-founder and CEO, WinSanTor, Inc., on restoring sensory fibers in peripheral neuropathy.

Issue 644: January 20, 2017

644Keith Murphy, Chairman and Chief Executive Officer, Organovo Holdings, Inc., on engineering human tissues for pharmaceutical screening.

Issue 643: January 13, 2017

643Catharina Boehme. M.D., Chief Executive Officer, Foundation for Innovative New Diagnostics, on developing diagnostics for poverty-related diseases.

Issue 641: December 23, 2016

641Geoff MacKay, President and CEO, AvroBio, Inc., on quickly bringing novel gene therapies into the clinic.

Issue 640: December 16, 2016

640a640bTed Yednock, Ph.D., Chief Scientific Officer, and Douglas Love, President and CEO, Annexon Biosciences, on targeting the complement pathway in neurodegenerative diseases.

Issue 639: December 9, 2016

639Linda Summerton, Ph.D., CEO, Immodulon Therapeutics Ltd., on triggering the immune system to fight cancer with mycobacteria.

Issue 638: December 2, 2016

638Aftab Ansari, Ph.D., Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, and Research Professor, Yerkes National Primate Research Center, on opening the potential for sustained control of HIV infection.

Issue 637: November 18, 2016

637Jack W. Reich, Ph.D., CEO and Co-founder, Renova Therapeutics, on gene therapy to normalize heart function in heart failure patients.

Issue 634: October 28, 2016

634Alex Haahr Gouliaev, Ph.D., Co-founder and Chief Executive Officer, Nuevolution AB, on efficiently identifying small-molecule drug candidates for difficult targets.

Issue 632: October 14, 2016

632Sylvain Martel, Ph.D., Professor and Director, NanoRobotics Laboratory, Department of Computer and Software Engineering, Institute of Biomedical Engingeering, Polytechnique, on delivering drugs to the optimal location inside tumors.

Issue 631: October 7, 2016

631Sau (Larry) Lee, Ph.D., Deputy Director (Acting), Office of Testing and Research, Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research, FDA, on encouraging industry adoption of continuous manufacturing.

Issue 629: September 23, 2016

629a629bGergely Tóth, Ph.D., M.B.A., Founder and Chief Executive Officer, and Thomas Sawyer, Ph.D., M.B.A., Chief Operations Officer, Cantabio Pharmaceuticals Inc., on pursuing novel treatment strategies for neurodegenerative diseases.

Issue 628: September 16, 2016

628Andrew M. Radin, Chief Business Officer & Co-Founder, TwoXAR, on using predictive algorithms to identify novel drug candidates.

Issue 627: September 9, 2016

627Jack A. Syage, Ph.D., CEO and Co-founder, ImmunogenX, on developing a treatment and diagnostic tools for celiac disease.

Issue 625: August 26, 2016

625Dane M. Chetkovich, M.D., Ph.D., Professor of Neurology and Physiology, Northwestern University Feinberg School of Medicine, on a new potential drug target for the treatment of depression.

Issue 623: August 12, 2016

623Christian Tidona, Ph.D., Managing Director, BioMed X Innovation Center, on creating innovative research teams to collaborate with industry.

Issue 621: July 29, 2016

621Anthony J. Filiano, Ph.D., Postdoctoral Researcher, Center for Brain Immunology and Glia, School of Medicine, University of Virginia, on uncovering the connections between the immune system, brain circuits, and behavior.

Issue 618: July 8, 2016

618Bharatt Chowrira, Ph.D., J.D., President, Synlogic, on developing programmable probiotics as a novel class of therapeutics.

Issue 617: June 24, 2016

617Layton Smith, Ph.D., Assistant Professor and Director, Florida Drug Discovery, the Florida Translational Research Program at the Sanford Burnham Prebys Medical Discovery Institute, on advancing the frontiers of academic drug discovery.

Issue 616: June 17, 2016

616Charles Swanton, FRCP, Ph.D., Group Leader, the Francis Crick Institute, on understanding tumor evolution to develop better treatment strategies.

Issue 612: May 13, 2016

612Jean-François Mouney, CEO and Chairman, GENFIT, on positioning Elafibranor as a first-line treatment in NASH.

Issue 610: April 29, 2016

610Joseph S. Beckman, Ph.D., Principal Investigator and Burgess and Elizabeth Jamieson Chair in Healthspan Research, Linus Pauling Institute, Distinguished Professor, Department of Biochemistry and Biophysics, and Director, Environmental Health Sciences Center, Oregon State University, on preclinical breakthroughs in ALS now heading into the clinic.

Issue 609: April 22, 2016

609Pablo Graiver, Founder and CEO, TrialReach, on making it easy for patients to connect to clinical trials.

Issue 608: April 15, 2016

608Guoping Feng, Ph.D., Investigator, McGovern Institute for Brain Research, and Poitras Professor of Neuroscience, MIT, and Director, Model Systems and Neurobiology, Stanley Center for Psychiatric Research at the Broad Institute, on uncovering the mechanisms underlying autism spectrom disorder.

Issue 603: March 11, 2016

603Robert Masella, Partner, Shearman & Sterling, on the outlook for M&A activity.

Issue 602: March 4, 2016

602William Flavahan, Ph.D., Postdoctoral Fellow, Massachusetts General Hospital and Harvard Medical School, on new insights into oncogene activation in IDH mutant gliomas.

Issue 601: February 26, 2016

601Niven R. Narain, Co-Founder, President & Chief Executive Officer, Berg LLC, on integrating big data to drive drug discovery and development.

Issue 600: February 19, 2016

600Apkar Vania Apkarian, Ph.D., Professor of Physiology, Northwestern University Feinberg School of Medicine, on reversing the remodeling of the brain associated with chronic pain.

Issue 599: February 12, 2016

599Jon Palfreman, Ph.D., author of Brain Storms, on tracking research developments in Parkinson’s, now as a patient.

Issue 595: January 15, 2016

595David Fellows, Chief Executive Officer and Board Member, NightstaRx Ltd., on developing gene therapies for inherited retinal dystrophies.

Issue 592: December 11, 2015

592Dallas E. Hughes, Ph.D., President, NovoBiotic Pharmaceuticals, LLC, on developing a platform for discovering new classes of antibiotics.

Issue 590: November 20, 2015

590Minoru Takasato, Ph.D., Senior Researcher at the Murdoch Childrens Research Institute, on creating a kidney organoid that contains all human kidney cell types.

Issue 589: November 13, 2015

589Joseph S. McCracken, D.V.M., Vice President of Business Development, Alkahest, Inc., on using young plasma to treat Alzheimer’s disease.

Issue 588: November 6, 2015

588Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies and Canada Research Chair in Genetics of Pain (Tier I) at McGill University, on the increasing placebo response over time in US clinical trials of neuropathic pain.

Issue 585: October 9, 2015

585Margarita Behrens, Ph.D., Staff Scientist, Salk Institute for Biological Studies, on the role of mGluR5 in the development of parvalbumin-positive interneurons and neurodevelopmental disorders.

Issue 584: October 2, 2015

584Kang Zhang, M.D., Ph.D., Professor of Ophthalmology and Chief of Ophthalmic Genetics, University of California, San Diego, on reversing cataracts with lanosterol.

Issue 583: September 25, 2015

583Thomas West, Project Director and Manager of Intellectual Property, Aprecia Pharmaceuticals Company, on a novel formulation to improve adherence for those with difficulty swallowing pills.

Issue 581: September 11, 2015

581Nathalie Donne, Director of Corporate Communication & Business Development, DBV Technologies, on meeting unmet needs in severe food allergies.

Issue 579: August 28, 2015

579Greg Duncan, President and Chief Executive Officer, Celtaxsys, Inc., on downregulating the neutrophil response in inflammatory disorders.

Issue 578: August 21, 2015

578Alexis C. Wallace, Co-founder, President, and Chief Executive Officer, Thrombolytic Science International, LLC, on extending the treatment window for stroke with greater safety.

Issue 576: August 7, 2015

576Tsuyoshi Inoue, PharmD, Associate Professor, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, on developing epilepsy treatment targeting the LDH metabolic enzyme.

Issue 574: July 24, 2015

574Luis A. Diaz, Jr., M.D., Associate Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, on mismatch repair deficiency and response to PD-1 inhibitors.

Issue 572: July 10, 2015

572Ted J. Kaptchuk, Professor of Medicine, Harvard Medical School, on investigating the genetic components of the placebo effect.

Issue 571: June 26, 2015

571Pascale Malgouyres, Pharm D, MSc, Chief Commercial Officer and Co-Founder, Poxel SA, on developing a pipeline of novel treatments for type 2 diabetes.

Issue 569: June 12, 2015

569Charles Magness, Ph.D., President and CEO, Kineta, Inc., on building a more efficient model of early-stage drug development.

Issue 567: May 29, 2015

567Andrew Vaillant, Ph.D., Chief Scientific Officer, RepliCor, on developing new treatments for Hepatitis B focused on subvirus particles.

Issue 566: May 22, 2015

566Konrad Glund, Ph.D., Co-founder and CEO, Probiodrug AG, on moving from research discovery to clinical development in Alzheimer’s disease.

Issue 565: May 15, 2015

565Raúl Insa, M.D., Ph.D., Founder & CEO, SOM Biotech SL, on screening existing drugs for new indications.

Issue 564: May 8, 2015

564William Moore., Ph.D., President and CEO, Innocrin Pharmaceuticals, Inc., on developing a new class of CYP17 lyase inhibitors.

Issue 562: April 24, 2015

562Jos Joore, Ph.D., Co-founder and Chief Business Officer, Mimetas B.V., on building high-throughput organs-on-chips.

Issue 560: April 10, 2015

560Rudolph E. Tanzi, Ph.D., Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School, and Director, Genetics and Aging Research Unit, Massachusetts General Hospital, and Doo Yeon Kim, Ph.D., Assistant Professor of Neurology, Harvard Medical School, and Assistant in Neurology, Genetics and Aging Research Unit, Massachusetts General Hospital, on a new and better preclinical model of Alzheimer’s disease.

Issue 559: April 2, 2015

559Alexey Terskikh, Ph.D., Associate Professor, Sanford-Burnham Medical Research Institute, on developing a treatment to regrow hair.

Issue 557: March 20, 2015

557Ali Tehrani, Ph.D., President & Chief Executive Officer, Zymeworks Inc., on demonstrating success with bispecific antibodies.

Issue 556: March 13, 2015

556Todd C. Brady, M.D., Ph.D., President and CEO, Aldeyra Therapeutics, Inc., on an aldehyde trap to treat inflammatory and other diseases.

Issue 555: March 6, 2015

555Brian M. Culley, Chief Executive Officer, Mast Therapeutics, Inc., on developing vepoloxamer for sickle cell disease and other indications.

Issue 553: February 20, 2015

553Cedric Francois, M.D., Ph.D., Co-founder & Chief Executive Officer, Apellis Pharmaceuticals, Inc., on being in the clinic with complement immunotherapy.

Issue 552: February 13, 2015

552Norikazu Eiki, Former Chairman, Bayer Yakuhin, on breaking through the status quo with revolutionary business models.

Issue 550: January 30, 2015

550Alexander Green, Ph.D., Assistant Professor, Department of Chemistry & Biochemistry, Arizona State University, on the design and application of toehold switches.

Issue 549: January 23, 2015

549Keith Blackwell, M.D., Ph.D., Associate Research Director, Joslin Diabetes Center, Professor, Department of Genetics, Harvard Medical School, and Faculty Member, Harvard Stem Cell Institute, on identifying biomarkers of longevity.

Issue 547: January 9, 2015

547Saad A. Naseer, M.D., President and CEO, The Jack and J.T Snow Scientific Research Foundation, on developing a potential treatment for Wolfram syndrome.

Issue 544: December, 2014

544Dendy Young, Chairman, Co-Founder and CEO, Perthera, on building an expert system for personalized cancer treatment.

Issue 543: December 5, 2014

543Holly Trautman, PharmD, MS, Co-founder, Aventine Consulting, LLC, on getting reimbursement dossiers right.

Issue 541: November 14, 2014

541Christoph Lengauer, Ph.D., Chief Scientific Officer, Blueprint Medicines, on building a pipeline of novel kinase inhibitors.

Issue 539: October 31, 2014

539Richard A. Bendis, President and CEO, BioHealth Innovation, Inc., on building a more vibrant life sciences cluster in Maryland.

Issue 536: October 10, 2014

536Johan Pontin, CEO, Beryllium, on making an impact in drug discovery.

Issue 535: October 3, 2014

535Julia P. Gregory, Chief Executive Officer, ContraFect Corporation, on developing novel approaches for treating infectious diseases.

Issue 534: September 26, 2014

534Jeffrey Stein, Ph.D., President and CEO, Cidara Therapeutics, Inc., on addressing unmet needs in infectious diseases.

Issue 533: September 19, 2014

533R.J. Tesi, M.D., President and CEO, FPRT Bio, on targeting neuroinflammation with a selective TNF inhibitor.

Issue 532: September 12, 2014

532Dario C. Altieri, Executive Vice President, The Wistar Institute, Director and Chief Scientific Officer, The Wistar Cancer Center, and Robert and Penny Fox Distinguished Professor of Cancer Biology, on unraveling the role of TRAP-1 in cell metabolism and tumor biology.

Issue 530: August, 29, 2014

530Paul J. Lombroso, M.D., Elizabeth Mears and House Jameson Professor in the Child Study Center, Professor of Neurobiology and of Psychiatry, and Director of the Laboratory of Molecular Neurobiology, Yale University School of Medicine, on inhibiting STEP as a potential treatment for Alzheimer’s Disease.

Issue 529: August 22, 2014

529Bruce M. Spiegelman, Ph.D., Stanley J. Korsmeyer Professor of Cell Biology and Medicine, Department of Cell Biology, Harvard Medical School, and Professor, Cancer Biology, Dana-Farber Cancer Institute, on prospects for a potential treatment for cancer cachexia by using tumour-derived parathyroid-hormone-related proteins.

Issue 528: August 8, 2014

528Eiji Yoshihara, Ph.D., Salk Institute for Biological Studies, on the significance of the institute’s research in the development of recombinant fibroblast growth factor 1 for the effective treatment of Type 2 Diabetes.

Issue 525: July 18, 2014

525Jon Meyer, Principal and Co-founder, Life Science Strategy Group, LLC, on launching the new OutsourcePharma Advisory Board, an anonymized social networking site that provides crowd-sourced reviews of the services of CROs for contract research outsourcing professionals at pharmaceutical companies.

Issue 524: July 11, 2014

524Allan Bradley, Ph.D., Founder and Chief Technical Officer, Kymab Limited, on his company’s Kymouse transgenic antibody platform, development programs for fully human monoclonal drugs, and partnering strategy.

Issue 523: June 27, 2014

523Rahul Aras, Ph.D., President and Chief Executive Officer, Juventas Therapeutics, Inc., on developing a pipeline of therapies focused on the treatment of heart failure, and his company’s lead development program and partnering strategy.

Issue 521: June 13, 2014

521Steve Orndorff, Ph.D., President and CEO, MicroBiome Therapuetics, LLC, on his company’s clinical development programs and approach to developing prebiotics to alter the microbiome in the treatment of a variety of diseases.

Issue 519: May 30, 2014

519Jennifer Doudna, Ph.D., Professor, Molecular and Cell Biology Department and Chemistry Department, University of California, Berkeley, Investigator, Howard Hughes Medical Institute, and Faculty Scientist, Lawrence Berkeley National Laboratory, on current research and potential future applications of the CRISPR-Cas system.

Issue 518: May 23, 2014

518Jianghong Rao, Ph.D., Associate Professor of Radiology, School of Medicine, Stanford University, on using a nanoparticle that can detect reactive oxygen species and reactive nitrogen species in vivo that could lead to improved methods for liver toxicity testing of drugs.

Issue 517: May 16, 2014

517Shivaani Kummar, M.D., Head, Developmental Therapeutics Clinic, National Cancer Institute, on the clinical trial Molecular Profiling based Assignment of Cancer Therapeutics (M-PACT), which determines whether selecting therapies based on genetic mutations can improve outcomes in patients with metastatic sold tumors.

Issue 513: April 17, 2014

513Mark Kessel, Co-founder, Symphony Capital, on employing a new structure for financing drug development.

Issue 512: April 11, 2014

512Adam Gazzaley, M.D., Ph.D., Associate Professor of Neurology, UCSF School of Medicine, on developing a video game to assess and improve cognitive performance.

Issue 510: March 28, 2014

shuhologoLyndon Lien, Ph.D., President and CEO of Balance Therapeutics, Inc., on reducing inhibitory signaling as an approach to improving cognitive performance in Down syndrome.

Issue 508: March 14, 2014

508John O’Rourke, Vice President of Marketing, Decisyon, Inc., on bringing together people and data to make and execute decisions.

Issue 507: March 7, 2014

507Craig M. Crews, Ph.D., Founder and Chief Scientific Advisor of Arvinas, Inc., and Professor, Yale University, using novel platforms to develop small molecules that can induce the degradation of disease-causing proteins.

Issue 505: February 21, 2014

505Warren Hosseinion, M.D., CEO of Apollo Medical Holdings, Inc., partnering to improve patient care in COPD.

Issue 502: January 31, 2014

shuhologoMichael Conn, Ph.D., Senior Vice President for Research, Associate Provost and Professor of Internal Medicine and Cell Biology, Texas Tech University Health Sciences Center, on using pharmacoperones to fix misfolded proteins.

Issue 501: January 24, 2014

501Yukinori Okada M.D., Ph.D., tenure-track lecturer at Tokyo Medical and Dental University, Department of Human Genetics and Disease Diversity, on seeking new possibilities of genome drug development.

Issue 500: January 17, 2014

500Warner C. Greene, M.D., Ph.D., Director, Gladstone Institute of Virology and Immunology, on finding a new potential pathway for HIV treatment.

Issue 498: December 20, 2013

498Magali Haas, M.D., Ph.D., M.S.E., Founder and CEO of Orion Bionetworks, on using big data for disease modeling in multiple sclerosis.

Issue 495: November 22, 2013

495Edwin Moses, Ph. D., Chairman and CEO of Ablynx, on developing novel proteins based on single-domain antibodies.

Issue 494: November 15, 2013

494Laura Shawver, Ph.D., CEO of Cleave Biosciences, on discovering and developing small molecules for targets in protein degradation pathways for cancer treatment.

Issue 491: October 25, 2013

491Sakhrat Khizroev, Ph.D., Professor and Vice Chair, Department of Immunology, College of Medicine, and Director, Center for Personalized Nanomedicine, Florida International University, on opening new horizons in medicine with magneto-electric nanoparticles.

Issue 489: October 11, 2013

489Dan Paterson, Chief Business Officer and Brian Sullivan, Corporate Development Director, Verastem, Inc., on selectively targeting cancer stem cells.

Issue 486: September 20, 2013

486Nancy Simonian, M.D., CEO of Syros Pharmaceuticals, on using super-enhancers to identify the genes driving disease and then developing drugs that inhibit or disrupt those targets.

Issue 485: September 13, 2013

485Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center, on opening new horizons for cancer immunotherapy.

Issue 483: August 30, 2013

483Derek A. Small, President and CEO and Joseph R. Moskal, Founder and Chief Scientific Officer of Nuarex Inc., on modulating the NMDA receptor for treatment of depression and other CSN disorders.

Issue 482: August 23, 2013

482Malcom Weir, Ph.D., Co-founder and CEO of Heptares Therapeutics, on targeting G protein-coupled receptors for Alzheimer’s Disease.

Issue 481: August 9, 2013

481Masashi Yanagisawa, M.D., Ph.D.,
Professor of University of Texas Southwestern Medical School and Tsukuba University, on developing orexin receptor agonist in the field of medicinal chemistry.

Issue 479: July 26, 2013

479Alain D. Baron, M.D., President and CEO, Elcelyx Therapeutics, on how their delayed release formulation of metformin, works.

Issue 477: July 12, 2013

477Jae Chung, Founder and CEO, goBalto Inc., on goBalto’s Tracker 2.0 cloud-based solution and the clinical study startup process.

Issue 472: May 31, 2013

472Paul L. Hallenbeck, Ph.D., President and CEO, Synbody Biotechnology Inc., on the company’s synbody platform and partnering strategy.

Issue 470: May 17, 2013

470John Holland, Senior Vice President, Business Development and Research, AMC Health, on using remote monitoring in clinical trials and how the FDA is viewing such innovations in trial design.

Issue 469: May 10, 2013

469Sapan Shah, Ph.D. President and Chief Executive Officer, ARMGO Pharma Inc., on the target mechanism in the company’s pipeline of novel compounds that utilize a defect in intracellular calcium regulation, and also on the company’s partnering strategy.

Issue 467: April 26, 2013

467Pamela Tenaerts, MD, MBA, Executive Director, The Clinical Trials Transformation Initiative (CTTI), on the company’s activities in identifying practices that will increase the quality and efficiency of clinical trials.

Issue 466: April 19, 2013

466Nathan Caffo, President, Presage Biosciences, on the company’s proprietary drug array platform for simultaneously analyzing multiple cancer drug candidates  within a single living tumor, and how pharmaceutical companies can use it to screen candidate compounds.

Issue 464: April 5, 2013

464John A. Latham, Ph.D., Chief Scientific Officer, and Mark J. Litton, Ph.D., MBA, Chief Business Officer and Treasurer, Alder Biopharmaceuticals, Inc, on the company’s development strategy for novel antibody therapeutics as a treatment for migraines.

Issue 463: March 28, 2013

463Sanae Shoji, Ph.D, Former Research Associate at University of Texas Southwestern Medical Center, on her pioneering publication, “Identification of a candidate therapeutic autophagy-inducing peptide.”

Issue 461: March 15, 2013

461James J. Collins, Ph.D., Co-founder, and Jeffrey D. Wager, M.D., Chairman, President and CEO, EnBiotix, Inc., on the company’s technology and partnering strategy for its novel anti-bacterial platforms.

Issue 459: March 1, 2013

459Destry Sulkes, M.D., Executive Vice President and Co-founder, Medivo Inc,. on the company’s services and how pharmaceutical companies can use them to deliver targeted communications to patients and doctors.

Issue 458: February 22, 2013

458Garret A. FitzGerald, M.D., Chair, Department of Pharmacology, and Director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, on his group’s research on molecular clocks in the regulation of biologic systems.

Issue 457: February 15, 2013

shuhologoJonathan Kil, M.D., Chief Medical Officer and Director, Sound Pharmaceuticals, Inc., on SPI’s development programs aiming to prevent and reverse hearing loss.

Issue 455: February 1, 2013

shuhologoThomas Kassberg, Chief Business Officer and Senior Vice President, Ultragenyx Pharmaceutical, on the company’s pipeline and strategy for developing treatments for rare and ultra-rare metabolic genetic disorders.

Issue 452: January 11, 2013

452Swati S. More, Ph.D, Research Associate, Center for Drug Design, University of Minnesota, on her findings from a study together with Professor Robert Vince, Ph.D.,  in which they found that a synthetic cofactor of glyoxalase was able to prevent neurodegeneration in a mouse model of Alzheimer’s disease.

Issue 450: December 21, 2012

450René Bernards, Ph.D., Division Head, Molecular Carcinogenesis, The Netherlands Cancer Institute, on his research findings for a pathway that appears to confer resistance to a variety of cancer drugs.

Issue 448: December 7, 2012

shuhologoChristopher A. Kroeger, M.D., President and CEO, Cardioxyl Pharmaceuticals, Inc, on the advantages of nitroxyl donors and the company’s development programs.

Issue 446: November 16, 2012

446Michael Jirousek, Ph.D., Co-founder and Chief Scientific Officer, Catabasis Pharmaceuticals, on the company’s lead program in  developing a pipeline focused on the treatment of inflammatory and metabolic diseases by employing its proprietary “linker” technology.

Issue 445 November 9, 2012

445D. Lynn Kirkpatrick, Ph.D., President and CEO, Ensysce Biosciences Inc., on the company’s technology and development programs for using single walled carbon nanotubes to deliver short interfering RNA (siRNA) for therapeutic applications in oncology.

Issue 443: October 26, 2012

443Elizabeth Iorns Ph.D., Co-Founder & CEO, Science Exchange, on the concept behind and goals for the company’s Reproducibility Initiative, a program designed to help scientists validate studies for publication or commercialization.

Issue 442: October 19, 2012

442Julian Bertschinger, Ph.D., Co-founder and Chief Executive Officer, Covagen AG, on the company’s technology platform for creatibng next-generation protein drugs, known as Fynomers, and its partnering strategy.

Issue 439: September 21, 2012

439Christopher Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation, on the company’s newly-acquired library of homing peptides and the company’s development programs.

Issue 438: September 14, 2012

438Joseph F. Clark, Ph.D., Professor of Neurology, University of Cincinnati, on about his research findings in cyclocreatine as a treatment for creatine transporter deficiency, and the pathway ahead for clinical development of a treatment for the disease.

Issue 436: August 31, 2012

436David Kaplan, Ph.D., Stern Family Professor of Engineering, Professor and Chair, Department of Biomedical Engineering, Tufts University, on his research into the properties of silk and its biomedical applications.

Issue 434: August 17, 2012

434Fumihiko Urano, M.D., Ph.D., Associate Professor, School of Medicine, Washington University, on his research into how thioredoxin-interacting protein (TXIP) molecules are linked to both ER stress and the production of IL-1β cytokine proteins within beta cells.

Issue 431: July 27, 2012

431Werner Lanthaler, Ph.D., Chief Executive Officer, Evotec AG, on the company’s strengths in drug discovery and approach to partnering.

Issue 430: July 20, 2012

430Michael Clayman, MD, Chief Executive Officer and Co-founder, Flexion Therapeutics, on the company’s strategic focus, the status of its development programs, and its partnering strategy.

Issue 427: June 29, 2012

427Berislav V. Zlokovic, M.D., Ph.D., Professor and Chair, Department of Physiology & Biophysics, and Director, Center for Neurodegeneration & Regeneration, Zilkha Neurogenetic Institute, Keck School of Medicine of USC on his research into the role of APOE4 in breakdowns in the blood-brain barrier.

Issue 424: June 1, 2012

424Rangaramanujam M. Kannan, Ph.D., Professor of Ophthalmology, Center for Nanomedicine/Wilmer Eye Institute, Johns Hopkins University School of Medicine, on results from his study on dendrimers for targeted treatment of neuroinflammation.

Issue 423: May 25, 2012

423Mark Bard, Co-Founder and Director, the Digital Health Coalition, on how pharmaceutical companies are using social media.

Issue 422: May 18. 2012

422Nicholas P. Tatonetti, Ph.D. Candidate in Biomedical Informatics, Stanford University, on his research into an approach for controlling bias when performing data mining on an observational dataset of drug adverse events.

Issue 421: May 11, 2012

421Anthony Goldbloom, Founder and CEO, Kaggle Inc., on the company’s business model and how it helps companies and institutions find new ways of analyzing data.

Issue 417: April 13, 2012

417Christian Zahnd, Ph.D., CEO, and Patrick Amstutz, Ph.D., Chief Business Officer, Molecular Partners AG, on the company’s pipeline for developing a novel class of protein therapeutics called DARPins, and its partnering strategy.

Issue 416: April 5, 2012

416Guido Lanza, President and CEO, Numerate, Inc., on the company’s approach to its in silico drug design, and its partnering model.

Issue 415: March 30, 2012

415Professor Akira Sawa, Director, Silvio O. Conte Neuroscience Research Center, Johns Hopkins Schizophrenia Center, on the center’s research into onset mechanisms for schizophrenia, focusing on both environmental and hereditary factors.

Issue 411: March 2, 2012

411Mason Tenaglia, Founder and Managing Director, The Amundsen Group, on the benefits of copay support programs for patients and manufacturers, and efforts to restrict the use of such programs.

Issue 410: February 24, 2012

410Paul M. Gilbert, Co-Founder and CEO, and Michael J. Detke, MD, PhD, Chief Medical Officer, MedAvante, Inc., on the company’s approach to bringing greater standardization to patient assessments in CNS clinical trials through the use of centralized raters, and its activities.

Issue 409: February 17, 2012

409George G. Montgomery, Managing Director, Sagent Advisors, on M&A trends in the biopharma sector.

Issue 401: December 16, 2011

401Hisataka Kobayashi, M.D., Ph.D., National Cancer Institute, Molecular Imaging Program, on research into photoimmunotherapy, and its future outlook as a new treatment for cancer.

Issue 400: December 9, 2011

400Bertrand C. Liang, M.D., Ph.D., M.B.A., Chief Executive Officer, Pfenex Inc., on the company’s unique protein expression platform that utilizes the microorganism Pseudomonas fluorescens in a high-throughput process for rapidly identifying high-quality protein production strains, and its partnering strategy.

Issue 398: November 18, 2011

398Brian Overstreet, Co-founder and President, AdverseEvents, Inc., on the company’s database of adverse drug events reported  the FDA, and its buisness model.

Issue 397: November 11, 2011

397Marcus Wilson, Pharm.D., President and Co-Founder of the HealthCore Unit of WellPoint, Inc., on the company’s major collaboration with AstraZeneca, and its activities.

Issue 395: October 28, 2011

395Daniel Conners, Chairman and President, Biothera Pharmaceutical Group, on the company’s development programs and partnering strategy.

Issue 394: October 21, 2011

394P. Ron Ellis, Co-Founder, President, and CEO, Endocyte, Inc., on the company’s technology platform for a pipeline of small molecule drug conjugates for treating cancer as well as inflammatory diseases, its development programs, and its partnering strategy.

Issue 393: October 14, 2011

393Richard A. Basile, CEO, BioPontis Alliance, LLC, on the company’s model and plans.

Issue 392: October 7, 2011

392David H. Kirn, M.D., Founder, President and CEO, Jennerex Biotherapeutics, Inc., on targeted oncolytic virus products for cancer, and the company’s lead compound, JX-594.

Issue 391: September 30, 2011

391Mark Pruzanski, M.D., Founder, President and CEO, Intercept Pharmaceuticals, Inc., on the company’s focus and partnering strategy.

Issue 390: September 23, 2011

390Atul Butte, M.D., Ph.D., Division Chief and Associate Professor in Pediatrics (Systems Medicine), Medicine and Pediatrics, Stanford University School of Medicine, on his research into how expression data could be used to find new indications for existing drugs, and a new company he has founded for commercial applications of the technology.

Issue 389: September 16, 2011

389Ramy Farid, Ph.D., President, and Shi-Yi Liu, Ph.D., Senior Vice President for Marketing, Schrödinger, LLC, on the company’s activities and its subsidiary in Japan.

Issue 387: August 26, 2011

387Shinichi Takeda M.D., Ph.D., Director, Translational Medical Center, National Center of Neurology and Psychology, on both the therapeutic potential of exon-skipping therapy for Duchenne muscular dystrophy and its continued doctoral research.

Issue 386: August 12, 2011

386Anthony McKinney, President, CEO and Co-Founder, Euthymics Bioscience, on the company’s development programs for novel medicines for major depressive disorder and ADHD, and its partnering strategy.

Issue 385: August 5, 2011

shuhologoGordon H. Busenbark, Senior Vice President and Chief Financial Officer, Inspiration Biopharmaceuticals, Inc. on the company’s development programs for a pipeline of treatments for hemophilia, and the structure of its partnership with Ipse.

Issue 383: July 22, 2011

383Anthony Costello, Chief Operating Officer, Mytrus, Inc. on the company’s approach for enabling patients to participate in clinical trials from the convenience of their own homes, and the benefits for patients and pharmaceutical companies.

Issue 382: July 15, 2011

382Philip E. Bourne, Ph.D., Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego on his findings and research approach to modeling the effects of a drug’s interactions with multiple receptors.

Issue 381: July 8, 2011

381Chip Clark, President and Chief Executive Officer, Genocea Biosciences, on the company’s vaccine technology platform, pipeline, and its partnering strategy.

Issue 380: July 1, 2011

380William J. Newell, CEO, Sutro Biopharma, Inc., on the company’s biochemical protein synthesis technology platform and its partnering strategy.

Issue 379: June 24, 2011

379Toru Hosoda, M.D., Ph.D., Associate Professor, Department of Medicine, National Institute of Science and Technology, Tokai University, on the first successful identification of stem cells from a human lung.

Issue 378: June 17, 2011

378Katherine S. Bowdish, Ph.D., Chief Executive Officer, Anaphore, Inc. on the company’s Atrimer platform, in-house development initiatives, and its partnering strategy.

Issue 376: June 3, 2011

376Shinichi Yachida, M.D., Ph.D., Research Associate, Department of Gastrointestinal Surgery, Kagawa University Hospital, on clarifying the genetic evolution and metastatic mechanisms of pancreatic cancer through genome analysis.

Issue 375: May 27, 2011

375Alan S. Klein, Executive Vice President, Corporate Development, Sequella Inc., on the company’s new antibiotic mechanism for treating TB and helicobacter pylori.

Issue 374: May 20, 2011

374Derek Chalmers, Ph.D., President and CEO, Cara Therapeutics, Inc., on the company’s development of a new analgesic without CNS Side Effects.

Issue 370: April 21, 2011

370Scott Johnson, President and Founder, Myelin Repair Foundation, on how the company is pioneering a new model for drug discovery and developing a new approach to treating multiple sclerosis.

Issue 369: April 15, 2011

369Dr. Krisztina Zsebo,
President and CEO, Celladon Corporation, on a genetically-targeted enzyme replacement therapy for treating heart failure.

Copyright © MSAPR Partners - Site Development AlpineWeb Design